| Literature DB >> 28077989 |
Daniel Pereira Bezerra1, Anne Karine Nascimento Soares2, Damião Pergentino de Sousa2.
Abstract
Bioactive natural products play critical roles in modern drug development, especially anticancer agents. It has been widely reported that various pharmacological activities of such compounds are related to their antioxidant properties. Vanillin is a natural substance widely found in many plant species and often used in beverages, foods, cosmetics, and pharmaceutical products. Antioxidant and anticancer potential have been described for this compound. Considering the importance of vanillin in the area of human health and food and pharmaceuticals sectors, in this review, we discuss the role of vanillin on redox status and its potential contribution to the prevention and the treatment of cancer.Entities:
Mesh:
Substances:
Year: 2016 PMID: 28077989 PMCID: PMC5204113 DOI: 10.1155/2016/9734816
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Chemical structure of vanillin (4-hydroxy-3-methoxybenzaldehyde).
Figure 2Overview of the antimutagenic effect of vanillin.
Summary of the main molecular targets of vanillin.
| Biological process | Molecular target |
|---|---|
| Cell proliferation and cell cycle | Akt↓, AP-1↓, ATM↓, aurora kinase B↓, calcyclin↓, Chk2↓, CTGF, cyclin A2↓, cyclin B↓, cyclin D1↓, ERK↓, H2A.X↓, INSIG1↓, I |
|
| |
| DNA damage, oxidative, and stress responses | CLK2↑, DDIT4↑, GCLC↑, GCLM↑, HMOX1↑, HSPA1B↑, PMS2↑, SLC7A11↑, TRIM16↑, UGP2↑, XRCC2↑, DNA-PK↓, DNMT3B↓, DUSP6↓, FGFR2↓, FZD2↓, NHEJ↓, PPP1R10↓, SLC35D2↓, UNG2↓ |
|
| |
| Apoptosis | p21↑, p53↑ |
|
| |
| Invasion and metastasis | MMP-9↓, PI3K↓ |
Akt, protein kinase B; AP-1, activator protein 1; ATM, ataxia telangiectasia mutated; Chk2, serine threonine kinase checkpoint kinase 2; CLK2, CDC-like kinase 2; CTGF, connective tissue growth factor; DDIT4, damage-inducible transcript 4; DNA-PK, DNA-protein kinase; DNMT3B, DNA (cytosine-5-)-methyltransferase 3 beta; DUSP6, dual specificity phosphatase 6; ERK, extracellular signal-regulated protein kinase; FGFR2, fibroblast growth factor receptor 2; FZD2, frizzled homolog 2 (Drosophila); GCLC, glutamate-cysteine ligase, catalytic subunit; GCLM, glutamate-cysteine ligase, modifier subunit; H2A.X, histone 2A family member X; HMOX1, heme oxygenase (decycling) 1; HSPA1B, heat shock 70 kDa protein 1B; INSIG1, insulin induced gene 1; IκB-α, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; JNK, c-jun N-terminal kinase/stress-activated protein kinase; JUND, jun D proto-oncogene; MAP2K2, mitogen-activated protein kinase kinase 2; MARK4, MAP/microtubule affinity-regulating kinase 4; MMP-9, matrix metalloproteinase 9; NF-κB, factor nuclear kappa B; NHEJ, non-homologous DNA end-joining; p21, cyclin-dependent kinase inhibitor 1; p38, p38/mitogen-activated protein kinase; p53, tumor suppressor protein 53; p65, transcription factor p65; PCNA, proliferating cell nuclear antigen; PI3K, phosphatidylinositol 3-kinase; PMS2, mismatch repair endonuclease; PPP1R10, protein phosphatase 1, regulatory subunit 10; S6RP, S6 ribosomal protein; SLC35D2, solute carrier family 35, member D2; SLC7A11, solute carrier family 7; TGFB1I1, transforming growth factor beta 1 induced transcript 1; TRIM16, tripartite motif-containing 16; UGP2, UDP-glucose pyrophosphorylase 2; UNG2, uracil-DNA glycosylase 2; XRCC2, DNA repair protein.